Skip to main content

J&J, Imerys Appeal to Reverse the $117 M Talc Verdict

J&J, Imerys Appeal to Reverse the $117 M Talc Verdict

J&J, Imerys Appeal to Reverse the $117 M Talc Verdict

Introduction

Defendants Johnson & Johnson and Imerys, its talc supplier, have appealed the $117 million New Jersey verdict announced earlier this month and deny the presence of asbestos in their products or that their talc can cause any form of cancer.
 
Mid-April, the New Jersey state jury awarded $117 million to the plaintiff, which was bifurcated as $37 million in compensatory damages and $ 80 Million in punitive damages. The case was heard in the Superior Court of the State of New Jersey, County of Middlesex. The plaintiff was seeking compensation for his diagnosis of mesothelioma (a cancer of the lung) allegedly caused by the asbestos present in the company’s Talcum Powder used over a long period. The jury agreed that the defendants showed reckless indifference in selling their Talcum powder that contained the controversial asbestos ingredient.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.